UBS raises target for Amgen stock to USD 470.00

Published on 10/14/2026 at 11:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

UBS raised its target from USD 430.00 to USD 470.00 on October 9, 2026. Amgen stock was at EUR 373.88 on October 14, 2026 with USD 222.8 billion market value.

Analyst target and reporting date

UBS raised its Amgen target from USD 430.00 to USD 470.00 on October 9, 2026.
Second-quarter revenue reached USD 10.05 billion, up 9.50 percent year over year.
Amgen stock trades at EUR 373.88 at 11:37 a.m. CEST at Lang & Schwarz on October 14, 2026.

Flatlay-Anordnung mit Aktienzertifikat, ISIN-Kärtchen, Petrischale, Pipette und Antikörper-Modell auf weißem Untergrund — Amgen Inc. (ISIN US0311621009) symbolisiert dieses Flatlay mit Aktienzertifikat, ISIN-Karte und Labormaterialien, Illustration mit AI erstellt.

Amgen (ISIN US0311621009) stock had its UBS target lifted from USD 430.00 to USD 470.00 on October 9, 2026, according to MarketBeat. UBS maintained a Buy rating, while the broader analyst view remained Hold with a consensus target of USD 389.71.

Analyst target reaches USD 470

The UBS move puts the new target USD 96.12 above the Lang & Schwarz euro quote only as a separate currency reference, so the two prices are not directly netted. MarketBeat also reported a USD 447.03 12-month high and USD 288.00 low for the Nasdaq-listed stock, providing a wide valuation backdrop.

The target revision follows Amgen's latest operating update rather than a same-day earnings release. It gives the market a fresh analyst reference before the next quarterly report, but the consensus target of USD 389.71 remains below UBS's USD 470.00 view.

What does the pipeline mean for growth?

Amgen's second-quarter 2026 revenue reached USD 10.05 billion, compared with USD 9.43 billion consensus, while earnings per share came to USD 6.29 against USD 5.62 expected, according to Yahoo Finance. Revenue increased 9.50 percent year over year in the quarter.

The same call showed a split in the portfolio: Repatha sales grew 37.00 percent year over year to USD 953.00 million, while Prolia and XGEVA combined sales fell 33.00 percent to USD 1.10 billion. The contrast explains why product mix matters as much as the headline revenue figure.

Three dates shape the next phase

On August 4, 2026, Amgen reported its second-quarter results with USD 10.05 billion in revenue and USD 6.29 earnings per share, according to Yahoo Finance. On September 22, 2026, Amgen announced that the Phase 3 OASIZ 301 trial of dazodalibep met its primary endpoint at Week 48, according to Amgen. On October 9, 2026, UBS raised its target from USD 430.00 to USD 470.00.

Next reporting date is November 3

MarketBeat lists November 3, 2026, as Amgen's expected third-quarter 2026 earnings date and gives consensus estimates of USD 5.76 earnings per share and USD 10.06 billion revenue. The company's OASIZ 303 Phase 3 study is expected to complete in the fourth quarter of 2026, according to Amgen's September 22 release.

Amgen stock stays near its yearly high

Amgen stock was trading at EUR 373.88 at Lang & Schwarz on October 14, 2026, at 11:37 a.m. CEST. The primary listing is Nasdaq, where the finance quote showed a USD 222.8 billion market capitalization on October 13, 2026, with a 52-week range of USD 288.00 to USD 447.03.

The further course of trading is shown by the continuously updated real-time quote of Amgen stock.